ulmonary arterial hypertension (PAH) is an obstructive vasculopathy in which vascular cells proliferate too rapidly or are resistant to apoptosis. PAH is also characterized by increases in inflammation, vasoconstriction, and fibrosis. Ultimately, these vascular changes increase right ventricular afterload, leading to heart failure and death.
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Pulmonary vascular cells from patients with PAH have adaptations that ensure that their high rates of proliferation are not thwarted by energy limitations, mitochondria-mediated apoptosis, or inadequate rates of mitotic fission. 1 Histological examination reveals the consequences of this proliferative diathesis, including intimal hyperplasia and plexiform lesions, medial hypertrophy, and adventitial fibrosis. The resulting endothelial dysfunction favors thrombosis and vasoconstriction; the hyperplasia of pulmonary artery smooth muscle cells (PASMCs) favors vasoconstriction; and the adventitial fibrosis results in stiff, noncompliant arteries.
Two articles in this issue of Circulation describe a metabolic adaptation that is good for the abnormal cell but bad for the patient, namely a shift in glucose metabolism called the Warburg phenomenon. Otto Warburg, a German Nobel Laureate, described the predilection of cancer to support its rapid growth by a reliance on glycolysis despite an abundance of available oxygen. Warburg metabolism is a failure of 2 fundamental pathways: glucose metabolism and mitochondrial oxygen sensing.
Glycolysis and glucose oxidation are normally coupled, meaning they occur in proportion to each other. The final products of glycolysis are ATP and pyruvate. Pyruvate enters the mitochondria via the mitochondrial pyruvate transporter and acts as the substrate for pyruvate dehydrogenase (PDH), which regulates glucose oxidation and supplies acetyl CoA to the Krebs cycle ( Figure) . Warburg metabolism represents a state of uncoupled glycolysis in that glycolysis is disproportionately elevated compared with mitochondrial pyruvate utilization and glucose oxidation. Warburg metabolism allows the cell a source of energy (glycolysis) while suppressing mitochondrial apoptosis and stimulating cell cycle progression.
The Warburg phenomenon also results from changes in the function of the acute and chronic oxygen-sensing systems of the cell. In response to rapid reductions in airway oxygen, the adjacent small pulmonary arteries (which are also critically involved in PAH) constrict. This diverts blood to better-oxygenated lung segments and optimizes Po 2 . Hypoxic pulmonary vasoconstriction 5 is triggered by dynamic decreases in the production of reactive oxygen species by the mitochondrial electron transport chain. This decreases generation of the diffusible redox mediator H 2 O 2 by mitochondrial superoxide dismutase 2 (SOD2), leading to redox regulation of oxygen-sensitive ion channels and enzymes, culminating in vasoconstriction. 5 When hypoxia is sustained, transcription factors, notably hypoxia-inducible factor (HIF-1α), mediate metabolic adaptation, notably shifting the lung to an energetic reliance on glycolysis. Although glycolysis is 8-fold less efficient than glucose oxidation, when upregulated, it generates sufficient ATP to maintain energy homeostasis. In cancer and PAH, epigenetically mediated changes in gene expression inhibit key genes involved in oxygen sensing and metabolism pathways despite abundant oxygen, creating a state of pseudohypoxia. 6 Epigenetic mechanisms alter gene expression without changing gene sequences. They include DNA methylation, mediated by DNA methyltransferases (DNMT), histone acetylation, and microRNAs (miRs). miRs are short, noncoding RNAs that are encoded by intronic DNA. They destabilize target mRNA, leading to decreased translation of a gene product. Lower levels of an miR translate to increased levels of its target mRNA product. These epigenetic mechanisms are networked and potentially reversible.
The Warburg metabolic phenotype is generated in PAH PASMCs by a network of epigenetic changes that include lung-specific upregulation of DNMT1 and DNMT3b. The resulting methylation of CpG islands in the SOD2 promoter 2 impairs transcription, reduces SOD2 levels, and decreases H 2 O 2 production. The resulting redox perturbations cause normoxic activation . This metabolic shift is associated with endothelial cell and fibroblast proliferation. The nuclear effects of PKM2, as a regulator of histone phosphorylation and potentiator of hypoxia-inducible factor-1α (HIF-1α) activation, were not studied. Likewise, the ability of PKM2 to promote cell proliferation by activating extracellular signal related kinase 1 and 2 (ERK1/2) was not assessed. An oxidant environment such as elevated H 2 O 2 levels inhibits PKM2 activity. B, The old cast. Increased lung-specific activation of DNA methyltransferase (DNMT) 1 and 3b methylates the superoxide dismutase 2 (SOD2) promoter and reduces SOD2 levels and electron transport chain (ETC) 1 activity. This impairs oxygen sensing and leads to normoxic HIF-1α activation. HIF-1α increases pyruvate dehydrogenase (PHD) kinase (PDK) expression and promotes pulmonary artery smooth muscle cell (PASMC) proliferation. 2 In addition, increased expression of miR25 and miR138 decreases function of the mitochondrial calcium uniporter complex (MCUC). This suppresses MCUC function, raises cytosolic calcium, and lowers intramitochondrial calcium, causing vasoconstriction and impairing PDH activity. Loss of the MCUC function also causes mitochondrial fission. These effects together promote PASMC proliferation and inhibit apoptosis.
of HIF-1α. HIF-1α upregulates key enzymes that inhibit oxidative metabolism, notably PDH kinase (PDK). Mitochondrial PDKs phosphorylate and inhibit PDH, which inhibits production of acetyl-CoA, and consequently, the cell shifts its source of ATP to uncoupled glycolysis. This pathway is called the DNMT/SOD2/HIF-1α/PDK/ PDH pathway. 2 In paired Circulation articles, Caruso et al 7 and Zhang et al 8 fill the Warburg stage with a new cast of Warburg players in pulmonary artery endothelial cells and fibroblasts, respectively. They show that pyruvate production is inhibited by a change in the activity of pyruvate kinase. Pyruvate kinase, the final and ratelimiting step in glycolysis, catalyzes phosphate transfer from phosphoenolpyruvate to ADP, producing pyruvate and ATP (Figure) . The mitochondrial supply of pyruvate is further compromised by downregulation of the MPT. Both groups demonstrate that this proglycolytic mechanism is stimulated by upregulation of a heterogeneous nuclear ribonucleoprotein, PTBP1 (polypyrimidine tract-binding protein). PTBP1 acts as a repressor and binds to the flanking sequences of exon 9, thus inhibiting the pyruvate kinase M1 (PKM1) isoform. The resulting increase in the PKM2/PKM1 ratio favors uncoupled glycolysis.
Caruso et al 7 used an unbiased systems biology approach to identify miRNA and proteomic profiles of blood outgrowth endothelial cells (BOECs) from patients with idiopathic PAH or heritable PAH caused by mutations of bone morphogenetic protein receptor type 2. They show that decreased production of miR-124 increases PTBP1 expression. miR-124 regulates PTBP1 in cancer cells.
9 PTBP1 alters pyruvate kinase gene splicing, increasing PKM2 and decreasing PKM1, leading to increased glycolysis in pulmonary artery endothelial cells and BOECs from patients with PAH and in a rodent PAH model (SU5416-hypoxia). This miR-124/PTBP1/PKM2 pathway is well established in the cancer literature in which it promotes glycolysis, increases cell proliferation, and causes apoptosis resistance. 9 Desai et al 10 found the switch from PKM1 to PKM2 in 16 tumor types.
The work by Caruso et al 7 offers 3 additional discoveries. First, readily accessible BOECs and hard-to-obtain human pulmonary artery endothelial cells have similar metabolic reprogramming, supporting the use of BOECs in PAH research. Second, loss of bone morphogenetic protein receptor type 2 drives proliferation by promoting Warburg metabolism. Thus, metabolic therapies may be an ideal way to treat PAH. Third, they address a controversy in the PAH field: What is the predominant change in endothelial cell fate in PAH: increased proliferation versus increased apoptosis? These theories are opposing, although this paradox may be related to temporal aspects of pathogenesis (ie, the increased apoptosis is postulated to be an early injury response, whereas the proliferative response is thought to occur later in the disease). In their study, Caruso et al 7 provide clear evidence that the net effect of the Warburg metabolic shift in PAH is accelerated endothelial cell proliferation.
Two observations emerge from the Caruso et al 7 data that were not discussed. First, they state that endothelial cells do not use glucose oxidation and interpret the benefits of inhibiting PKM2 solely as reflecting decreased glycolysis. However, in PAH BOECs, there was suppression of glucose oxidation, and this was reversed by both miR-124 mimic and siPTBP1 ( Figure  VIIH) . 7 Thus, endothelial cells may be quantitatively less reliant on glucose oxidation than PASMCs, but if a cell has mitochondria and is not "warburgian," it will oxidize glucose. Second, although the study focuses on the miR-124/PTBP1/PKM pathway in endothelial cells, examination of the PASMCs shows identical upregulation of PTBP1 (Figures 3 and 8 ). 7 Zhang et al 8 show that this miR-124/PTBP1/PKM2/ Warburg pathway creates a similar proliferative phenotype in fibroblasts derived from patients with PAH or calves with hypoxic pulmonary hypertension. Zhang et al 8 also show that mitochondrial pyruvate uptake is diminished as a result of MPT downregulation, as occurs in cancer. 11 They conclude that miR-124-mediated PTBP1 upregulation underlies the increase in PKM2/PKM1 in PAH fibroblasts. Unlike Caruso et al, 7 they found no increase in absolute expression of PKM2; rather, the ratio shift was driven largely by PKM1 downregulation. 8 This PKM isoform shift both increased glycolysis and suppressed glucose oxidation. Inhibiting PKM2 in fibroblasts enhanced mitochondrial respiratory activity and rescued complex I activity. Both Warburg metabolism and increased fibroblast proliferation were reversed by normalizing the PKM2/PKM1 ratio, achieved by miR-124 overexpression or PTBP1 knockdown.
This Warburg shift also accounted for inflammatory signaling in the fibroblast. Inhibiting the miR-124/ PTBP1/PKM pathway reduces macrophage interleukin-1β expression, consistent with a dynamic glycolyticmitochondrial interaction between fibroblasts and inflammatory cells in PAH. This is consistent with findings in colorectal cancer, in which PKM2 is an inflammatory mediator, acting through signal transducer and activator of transcription 3 signaling. 12 The Zhang et al 8 article also hints at the therapeutic relevance of this pathway. The PKM2 tetramer has greater activity than the dimeric form. 13 Zhang et al 8 stabilized the enzyme in its tetrameric form using TEPP-46, a small molecule, and shikonin, a Chinese herbal remedy. These interventions promote coupled glycolysis and attenuate the proliferative phenotype. One limitation shared by both these elegant studies is the lack of in vivo evaluation of the therapeutic impact in a preclinical PAH model. The lack of this intervention is surprising because this pathway is de-ranged in the SU5416 rat model. It is feasible to deliver modified miRs and siRNA to the lung vasculature by nebulization with therapeutic benefit. 3, 4 Therapeutic interventions in other epigenetic Warburg pathways in PAH have been tested. For example, the DNMT/ SOD2/HIF-1α/PDK/PDH pathway can be inhibited with decitabine, dichloroacetate, or anti-miRs. These interventions reduce cell proliferation, increase apoptosis, and regress experimental PAH.
FUTURE DIRECTIONS
The articles leave several important areas to address in future studies.
First, although both studies focus on miR-124 and PTBP1 as regulators of the metabolic switch, PKM2 is also directly regulated by DNA methylation, transcription factors, and PKM2-specific miRs, including miR-122, -133a, -133b, and -326 ( Figure) . 9 It is unknown whether these mechanisms are important to PKM2 dysregulation in PAH.
Second, although the authors acknowledge that some of the observed Warburg effect likely reflects the pseudohypoxic state (related to HIF-1α) originally described in PAH PASMCs, 2 they do not study the interactions between these pathways. The PKM2 isoform is a transcriptional coactivator of HIF-1α and increases HIF-1α activity by enhancing its binding to hypoxia response elements.
14 It would be profitable to see how the miR-124/PTBP1/PKM and DNMT/SOD2/HIF-1α/PDK/ PDH pathways interact in PAH.
Third, although the authors propose that the proliferative effects of PKM2 are mediated through altered metabolism, there are 5 other mechanisms by which pyruvate kinase may regulate cell accumulation. First, although not assessed in these articles, it is likely that PKM2 reduces mitochondria-mediated apoptosis, as it does in cancer. 15 Second, in addition, PKM2 is the cytosolic receptor for thyroid hormone, 16 which is relevant because PAH is associated with a very high prevalence of thyroid disease. Third, PKM2 is a protein kinase that activates extracellular signal related kinase 1 and 2, thereby stimulating mitosis. 17 Fourth, in response to stimuli that abound in PAH and cancer such as activation of platelet-derived growth factor receptors, PKM2 translocates to the nucleus. 18, 19 Nuclear PKM2 activates β-catenin and induces c-Myc expression. c-Myc reinforces glycolysis by upregulation of the glucose transporter GLUT1 and lactate dehydrogenase A. Nuclear PKM2 also phosphorylates histones and regulates cyclin D1 expression, accelerating the G1-S phase transition. 9 There is precedent for metabolic enzymes acting within the nucleus, notably the elegant demonstration that nuclear PDH generates the acetyl-coA required for histone regulation. 20 Fifth, PKM2 also increases glutaminolysis. This represents an energetic compensation for the loss of mitochondrial ATP and, in cancer, promotes cell survival and cell growth. In the pressure-overloaded right ventricle, induction of glutaminolysis promotes hypertrophy and hypokinesis and suppresses glucose oxidation.
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CONCLUSIONS
The miR-124/PTBP1/PKM2 pathway joins the DNMT/ SOD2-/HIF-1α/PDKPDH pathway and several others epigenetic pathways as the means by which abnormal pulmonary vascular cells achieve a Warburg metabolic state that promotes cell proliferation. Warburg metabolism and its epigenetic regulators are high-value therapeutic targets in PAH.
